Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202

Autor: Upton, K., Johnson, S., Saemann, M., Koletar, S. L., Gochnour, D., Bolivar, H. H., Pittard, D., Ray, G., Venuto, C. S., Smith, K. Y., Hoffman, J., Feinberg, J., Morgan, M., Fischl, M., Jackson, B., Tebas, P., Navarro, S., Patterson, K., Currin, D., Daar, E. S., Funk, C. A., Saag, M., Collier, A. C., Morse, G. D., Mollan, K., Tierney, C., Kim, G.-Y., Ma, Q., Seefried, E., Sax, P. E., Santos, B., Thomas, A.
Jazyk: angličtina
Rok vydání: 2014
Předmět:
DOI: 10.17615/xwmt-wm96
Popis: It is uncertain whether HIV-1 antiretroviral exposure and clinical response varies between males and females or different race/ethnic groups. We describe ritonavir-enhanced atazanavir pharmacokinetics in relation to virological failure, safety and tolerability in treatment-naive individuals to investigate potential differences.
Databáze: OpenAIRE